Investor Relations
Jul 16, 2018
OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada MORE >>
Jun 11, 2018
OPKO Health Completes Enrollment in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes and Obesity MORE >>
May 18, 2018
OPKO Plans to Address Draft Local Coverage Determination Published by Novitas Solutions for 4Kscore Test MORE >>
May 08, 2018
OPKO Health Reports First Quarter 2018 Financial Results MORE >>

Press Releases

All Releases
OPKO Health to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Jan 05, 2015
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) today announced that senior management will present at the 33 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015 at 4:00 PM PT . A live audio webcast of the presentation will be accessible through the OPKO Investor
OPKO and Pfizer Enter into Global Agreement for OPKO's Long-Acting Human Growth Hormone (hGH-CTP)
Dec 15, 2014
  • hGH-CTP in global clinical development for the treatment of pediatric and adult growth hormone deficiency (GHD)
  • hGH-CTP has potential to reduce dosing frequency of human growth hormone to single weekly injection from current standard of daily injection
  • OPKO to receive upfront payment of $295 million and eligible to receive up to an additional $275 million upon achievement of regulatory milestones
  • Upon Pfizer's commercialization of hGH-CTP, OPKO is eligible to receive royalty and/or profit sharing payments
  • Pfizer to obtain exclusive license to commercialize hGH-CTP globally
OPKO Health to Present at the Oppenheimer 25th Annual Healthcare Conference
Dec 03, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Oppenheimer 25 th Annual Healthcare Conference on Wednesday, December 10, 2014 at 10:20 AM (ET) . OPKO's senior management will provide a review of recent corporate developments.
OPKO Health to Present at the Jefferies 2014 Global Healthcare Conference
Nov 13, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, November 19, 2014 at 4:20 PM GMT in London . About OPKO Health, Inc. OPKO is a multi-national biopharmaceutical and diagnostics
OPKO Announces Publication of Large, Prospective, Multi-Institutional Clinical Validation of the 4Kscore™ Test for High Grade Prostate Cancer in the United States
Nov 10, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the online publication of a multi-institutional, prospective study of the 4Kscore Test in the journal European Urology . The results of the study demonstrated that the 4Kscore provides a patient with accurate and personalized
OPKO To Hold Conference Call on November 10, 2014
Nov 07, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK ) will hold a conference call to provide a business update and discuss its third quarter 2014 financial results on Monday, November 10, 2014 , before the market opens. OPKO's senior management team will host a conference call and live audio
OPKO Announces Third Quarter Operating and Financial Results
Nov 07, 2014
Rayaldee™ Meets Primary Endpoints in Both Pivotal Phase 3 Trials; NDA Submission Planned for Q4 2014 Rayaldee Results to be Presented at American Society of Nephrologists Meeting Clinical Trial Start for Rayaldee as Adjunctive Cancer Therapy to Begin in Q4 2014 European Marketing Commenced for
Neovasc, an OPKO Investee, Receives FDA Conditional Approval to Initiate TIARA-I Trial in U.S.: A Multinational, Multicenter Early Feasibility Trial of the TiaraTM Transcatheter Mitral Valve
Oct 09, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK ) announced that its investee, Neovasc, has received conditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate the U.S. arm of its TIARA-I Early Feasibility Trial for the Company's
OPKO Health Supports National Prostate Cancer Council Legislation
Sep 29, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) is pleased to lend its support to the legislation introduced in the United States Senate on September 16, 2014 by Senators Jeff Sessions (R-AL) and Barbara Boxer (D-CA) legislating the formation of the National Prostate Cancer Council (NPCC).
OPKO's Second Rayaldee Phase 3 Trial Meets Primary Endpoints
Sep 23, 2014
Targeted Response Rate Achieved for Plasma Parathyroid Hormone Reduction Favorable Adverse Event Profile Consistent with First Phase 3 Trial New Drug Application Submission to U.S. FDA Planned for End of 2014 MIAMI --(BUSINESS WIRE)-- OPKO Health , Inc. (NYSE: OPK), announced successful top-line
OPKO Launches the 4Kscore Test in Europe
Sep 15, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the European launch of the 4Kscore ™ Test, the only blood test that accurately identifies risk for aggressive prostate cancer, through its wholly owned subsidiary, OPKO Health Spain. The launch in Europe follows the U.S.
Data Supporting Once-Weekly Dosing of hGH-CTP in Growth Hormone Deficient Pediatric Population to be Presented as a Late Breaking Presentation at the European Society of Paediatric Endocrinology Conference
Sep 11, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK), today announced that the abstract "Top Line Results of Once-Weekly , CTP-Modified Human Growth Hormone (MOD-4023): Phase 2 Dose Finding Study in Children with Growth Hormone Deficiency (GHD)" has been selected for late breaking oral
OPKO Licensee TESARO Submits New Drug Application for Rolapitant
Sep 08, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK), reported that its licensee, TESARO, Inc. (Nasdaq:TSRO), has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of oral rolapitant, an investigational neurokinin-1 (NK-1) receptor antagonist in
OPKO Announces Second Quarter Operating and Financial Results
Aug 11, 2014
Rayaldeev™ Meets Primary Endpoints in First Pivotal Phase 3 Trial; Top Line Data From 2 nd Pivotal Phase 3 Trial to be Available September 2014 ; NDA Submission on Track for Q4 2014 IND Submitted for Rayaldee as Adjunctive Cancer Therapy Positive Pediatric Phase 2 Data Reported for hGH-CTP Once
Rayaldee Phase 3 Trial Meets Primary Endpoints
Aug 11, 2014
Top-line Data from Second Identical Pivotal Phase 3 Trial Expected in September 2014 New Drug Application (NDA) Submission to the U.S. FDA on Track for End of 2014 MIAMI --(BUSINESS WIRE)-- OPKO Health , Inc. (NYSE: OPK), announced successful top-line results from the first pivotal phase 3 trial
OPKO Submits IND for Rayaldee™ as Adjunctive Cancer Therapy
Aug 07, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health , Inc. (NYSE: OPK), announced the submission of an Investigational New Drug (IND) Application to the United States (U.S.) Food and Drug Administration (FDA) under which Rayaldee ™ will begin clinical evaluation as an adjunctive therapy for the prevention of
OPKO to Announce Top Line RAYALDEE Results and Second Quarter 2014 Financial Results on August 11, 2014
Aug 07, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK ) will announce top line data from the first of two identical pivotal Phase 3 clinical trials for RAYALDEE™ and its second-quarter 2014 financial results on Monday, August 11, 2014 , after the market closes.
OPKO Granted Patent from US Patent & Trademark Office for RAYALDEE
Jul 22, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK), a multinational biopharmaceutical and diagnostics company, today announced that the United States Patent and Trademark Office granted OPKO a patent covering RAYALDEE ™, the Company's product to treat secondary hyperparathyroidism (SHPT) in
OPKO's Long-Acting Clotting Factor VIIa-CTP Receives Positive Opinion For Three Orphan Drug Designations in Europe
Jul 09, 2014
Broad Designations for Treatment of Hemophilia A & B with Inhibitors As Well As Congenital Factor VII Deficiency 10-Year Marketing Exclusivity In Europe Upon Product Launch Adds To Previously Granted Orphan Drug Designation in The U.S. MIAMI --(BUSINESS WIRE)-- OPKO Health , Inc. (NYSE:OPK) today
OPKO Granted Patent from European Patent Office for Lagova™
Jun 27, 2014
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK), a multinational biopharmaceutical and diagnostics company, today announced that the European Patent Office granted OPKO a patent covering the company's long-acting CTP-enhanced human growth hormone product (Lagova), including composition of
Displaying 161 - 180 of 355